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ABSTRACT Staphylococcus aureus is frequently isolated in the setting of infections of

indwelling medical devices, which are mediated by the microbe’s ability to form bioﬁlms on a variety of surfaces. Bioﬁlm-embedded bacteria are more resistant to antimicrobial agents than their planktonic counterparts and often cause chronic infections and sepsis, particularly in patients with prolonged hospitalizations. In this
study, we demonstrate that sustained nitric oxide-releasing nanoparticles (NO-np) interfere with S. aureus adhesion and prevent bioﬁlm formation on a rat central venous catheter (CVC) model of infection. Confocal and scanning electron microscopy
showed that NO-np-treated staphylococcal bioﬁlms displayed considerably reduced
thicknesses and bacterial numbers compared to those of control bioﬁlms in vitro
and in vivo, respectively. Although both phenotypes, planktonic and bioﬁlmassociated staphylococci, of multiple clinical strains were susceptible to NO-np, bacteria within bioﬁlms were more resistant to killing than their planktonic counterparts. Furthermore, chitosan, a biopolymer found in the exoskeleton of crustaceans
and structurally integrated into the nanoparticles, seems to add considerable antimicrobial activity to the technology. Our ﬁndings suggest promising development and
translational potential of NO-np for use as a prophylactic or therapeutic against bacterial bioﬁlms on CVCs and other medical devices.
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S

taphylococcus aureus is a Gram-positive bacterium that commonly colonizes human
nasal membranes and skin. Methicillin-resistant S. aureus (MRSA) was ﬁrst described
in 1961 (1), and its prevalence has gradually increased within the population, currently
representing a major cause of both community- and health care-associated infections,
resulting in high morbidity and mortality (2). Although S. aureus is primarily acknowledged for its acute pathogenic characteristics, the microorganism’s capacity to cause
chronic infections of host tissues or medical implants is based on its ability to adhere
to different types of surfaces and form bioﬁlms (3–5). In particular, device-related
infections (e.g., related to central venous catheters [CVCs], hemodialysis catheters,
prosthetic heart valves, cardiac pacemakers, prosthetic joints, and cerebrospinal ﬂuid
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shunts) are difﬁcult to eradicate given that microbial bioﬁlms are surrounded by an
exopolymeric matrix (EPM) that confers resistance to the host immune response and
antimicrobial drugs (6). Hence, S. aureus has emerged as a leading cause of prosthetic
device infections (7, 8).
Approximately 250,000 CVC-related infections occur annually in the United States,
with an attributable mortality ranging from 12 to 25% in critically ill patients (9). CVCs
are a high risk for staphylococcal bioﬁlm-related infection due to the presence of
bacteria in the skin and because they are in direct contact with the patient’s bloodstream; it is therefore no surprise that this organism is the leading cause of bloodstream
infections in the United States (7). MRSA and methicillin-sensitive S. aureus (MSSA)
cause 7.4% and 4.7%, respectively, of the central line-associated bloodstream infections
(10). Current IDSA guidelines for the treatment of catheter-associated S. aureus infections advocate for line removal to facilitate more rapid clearance of the bloodstream
and better prognosis (11). The health care costs associated with catheter-related MRSA
infections are estimated to range between $6,916 and $60,000 per patient (12).
Moreover, antimicrobial resistance is associated with higher charges, prolonged hospital stays, and increased death rates (13). Consequently, there is a need for innovative
strategies to combat S. aureus catheter-related infections, especially bioﬁlm-related
infections that exacerbate morbidity, resulting in high mortality (7).
Nitric oxide (NO) is a diatomic, lipophilic gaseous molecule with numerous functions, including cellular signaling, vascular modulation and homeostasis, immune
function, pro- and anti-inﬂammatory properties, and both bactericidal and bacteriostatic properties (14, 15). Our group has previously characterized and extensively
demonstrated the therapeutic potential of NO generated and delivered by a siliconbased nanoparticle platform (NO-np) for the treatment of diverse infectious diseases,
including Gram-positive and -negative bacterial and fungal skin and soft tissue infections (16–20). While a number of NO-donating compounds have emerged, been
evaluated in vitro, and shown efﬁcacy against bioﬁlm-forming pathogens, many suffer
from various limitations ranging from inadequate release capacity to stability and safety
concerns (21–25). A deﬁning feature of the NO-np is that it is a true NO generator, not
an NO-donating compound with potential cytotoxicity, such as is seen with diazeniumdiolates (21, 25). The nanoparticles uniquely facilitate the formation of NO from
nitrite salt through a stable and potent NO intermediate, N2O3 nanoparticles. In fact,
the simplicity and the stability of the nanoparticles make them a very attractive
treatment modality under many conditions, including combat or disaster situations,
especially since they have proven efﬁcacy in vitro and in vivo in animal models against
multidrug-resistant bacteria that are exceedingly difﬁcult to treat with currently available antimicrobials (16, 17). Additionally, safety assessments using cell culture (26) and
animal (27) models have demonstrated minimal cytotoxicity and no clinical adverse
events, respectively.
Several NO-np platforms have been synthesized and used for antibioﬁlm applications, highlighting the feasibility and importance of developing these technologies to
prevent and ﬁght contamination of prosthetic devices (23, 25, 28–30). Here, we used a
CVC MRSA bioﬁlm model to study the effectiveness of NO-np in preventing and
eradicating MRSA bioﬁlms (31, 32). Our ﬁndings strongly suggest that this nanotechnology can potentially be developed and used in the future as a therapeutic agent for
the prevention and treatment of catheter-associated MRSA bioﬁlm infections.
RESULTS
NO-np inhibit MRSA 6498 cells. The efﬁcacy of an antimicrobial is dependent on
the concentration used, contact time of exposure, and cell’s metabolic activity (Fig. 1).
The antibacterial effects of increased concentrations of NO-np on planktonic cells of
MRSA clinical strain 6498 were assessed in real-time (Fig. 1A). Cellular growth was
reduced by 40% after incubation with 2.5 mg/ml of NO-np and by 50% at concentrations of ⱖ5 mg/ml (P ⬍ 0.0001). We also evaluated the efﬁcacy of NO-np against MRSA
6498 planktonic cells according to their contact time of exposure. NO-np was found to
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FIG 1 Nitric oxide-releasing nanoparticles (NO-np) inhibit methicillin-resistant S. aureus (MRSA) strain
6498 cells. (A) MRSA strain 6498 planktonic cells were grown on polystyrene microtiter plates for 24 h at
37°C in the absence (control; Ctrl) or presence of increasing NO-np (1.25, 2.5, 5, 10, and 20 mg/ml)
concentrations. Each point represents the average of three spectrophotometric measurements (optical
density at 600 nm [OD600]), and error bars indicate standard deviations (SDs). Statistical signiﬁcance (*,
P ⬍ 0.0001) was calculated by analysis of variance (ANOVA). (B) The effect of NO (5 mg/ml) on MRSA
growth kinetics was determined using spectrophotometry (OD600) for 24 h. Each symbol represents the
average of three measurements for control, np, or NO-np treatment, and error bars indicate SDs.
Statistical signiﬁcance (P ⬍ 0.05 in comparing the results of control, np, and NO-np treatments) was
calculated by multiple t tests. *, higher OD compared to np group; #, higher OD compared to NO-np
group. (A and B) The initial inoculum was 106 staphylococci per well.

be an effective antimicrobial against MRSA strain 6498, with bacterial cell growth
substantially reduced after 6 h of exposure (P ⬍ 0.05) (Fig. 1B). After 8 h of exposure,
NO-np reduced cellular growth by 50% compared to the growth of the untreated
control, and the reduction remained constant after 24 h (P ⬍ 0.05). Similarly, bacteria
grown in the presence of 5 mg/ml of np demonstrated approximately 20% reduction
in microbial growth (P ⬍ 0.05), strongly suggesting that the chitosan associated with
the nanoparticles interferes with MRSA growth (16, 33). Unpublished data in our
laboratory using nanoparticles with and without chitosan indicate that 15 to 25% of the
total microbial growth inhibition can be attributed to the biopolymer.
NO-np efﬁcacy against S. aureus planktonic and bioﬁlm-associated cells. S. aureus
cells within mature bioﬁlms formed by several strains were signiﬁcantly more resistant
to NO-np than planktonic cells when viability was determined by counting the number
of CFU (Fig. 2). On average, the viability of planktonic and bioﬁlm-related bacteria was
substantially reduced when bioﬁlms were treated with 1.25 and 2.5 mg/ml of NO-np.
However, the viability of cells within bioﬁlms was signiﬁcantly higher than that of their
planktonic counterparts after treatment with similar concentrations of NO-np (P ⬍
0.05). Planktonic and bioﬁlm-related cells were killed at signiﬁcant rates at 5 mg/ml of

FIG 2 NO-np are effective against S. aureus planktonic and bioﬁlm-associated cells. The levels of bacterial
viability of six distinct S. aureus clinical isolates in bioﬁlms and planktonic cells were determined by CFU
counts. Both phenotypes were exposed to 1.25, 2.5, and 5 mg/ml of np or NO-np for 24 h, and their
viability was compared to that of bacteria (5 ⫻ 106 bacteria per ml) incubated in medium alone. For
bioﬁlm formation, the initial inoculum was 106 staphylococci per well. The bioﬁlms were allowed to form
for 24 h. Each symbol represents the result for a single strain. Black lines are the averages of the results for
the six isolates, and error bars denote SDs. Statistical signiﬁcance (*, P ⬍ 0.05 in comparing the results
for bioﬁlms and planktonic cells) was calculated by multiple t tests and adjusted by using the Holm-Sidak
method. This experiment was performed twice, with similar results obtained each time.
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FIG 3 NO-np interferes with adhesion of MRSA strain 6498 to glass-bottom plates. (A) Adhesion to a solid substrate
was investigated using poly-D-lysine-coated 35-mm glass-bottom plates and confocal microscopy. Bacteria (106 per
plate) were allowed to adhere for 90 min in the absence and presence of np or NO-np. After treatment, the plates
were rinsed to remove nonadherent cells, attached bacteria were stained with SYTO9 (green ﬂuorescence), images
were taken, and the numbers of attached bacteria were counted. Then, the percentage of attached bacteria treated
with np or NO-np was calculated relative to the count for the untreated control. Bars represent the averages of ﬁve
replicates, and error bars denote SDs. Statistical signiﬁcance (**, P ⬍ 0.01; ****, P ⬍ 0.0001) was calculated by
ANOVA. (B) Representative images of adhesion by control and np- or NO-np-treated MRSA cells. Scale bar, 10 m.
This experiment was performed twice, with similar results obtained each time.

NO-np. Additionally, both phenotypes showed susceptibility to 5 mg/ml of control np,
which suggests that the chitosan incorporated into the nanoparticles may offer some
degree of antimicrobial activity, as previously demonstrated (16, 33).
NO-np interferes with adhesion of MRSA strain 6498 to solid substrates. We
investigated the ability of MRSA 6498 to adhere to the surface of a glass-bottom plate
after NO-np treatment (Fig. 3). NO-np signiﬁcantly decreased the ability of microbial
cells to adhere to glass-bottom plates relative to the adhesion ability of np-treated (P ⬍
0.0001) and untreated cells (P ⬍ 0.0001) (Fig. 3A). Likewise, there was an approximately
30% reduction in adhesion of bacteria incubated with np compared to the adhesion of
untreated cells (P ⬍ 0.01). Confocal microscopy conﬁrmed that np and NO-np affect the
interaction of MRSA with the solid substrate compared to the interaction of untreated
controls (Fig. 3B), revealing that chitosan plays an important role in the antibioﬁlm
formation efﬁcacy of the nanoparticles (16, 33).
Bacteria within mature bioﬁlms are effectively killed by NO-np. The efﬁcacy of
NO-np on MRSA 6498 mature bioﬁlms grown on polystyrene microtiter plates was
investigated using both the ﬂuorescein diacetate (FDA) assay and confocal microscopy.
Microbial bioﬁlms treated with NO-np showed a signiﬁcant reduction in cell viability
compared to that of the untreated (P ⬍ 0.01) or np-treated (P ⬍ 0.05) control (Fig. 4A).
For example, the viability of staphylococcal bioﬁlms was reduced 51.8% after treatment
with 5 mg/ml of NO-np. Confocal microscopic examination was used to visualize and
quantify the effects of NO-np on MRSA 6498 bioﬁlm structure (Fig. 4B to D). Regions of
red ﬂuorescence (concanavalin A-Texas Red conjugate) represent EPM (34), and the
green ﬂuorescence (SYTO9) indicates bacterial cells (Fig. 4C and D). MRSA bioﬁlms
grown in the absence of treatment showed a robust bioﬁlm with homogeneous
distribution of bacterial cells and extracellular matrix (Fig. 4C and D). Bioﬁlms exposed
to np demonstrated a thickness similar to that of the untreated control (P ⬍ 0.01) (Fig.
4B), with widespread areas consisting of clumped matrix (Fig. 4C) mostly located on the
top of the structure, and bacteria in the deeper areas of the bioﬁlm (Fig. 4D). However,
NO-np-treated bioﬁlms displayed a substantially thinner architecture than control
bioﬁlms (Fig. 4B) (P ⬍ 0.01), with multiple areas consisting of clumps of extracellular
matrix (Fig. 4C and D).
NO-np interfere with MRSA strain 6498 bioﬁlm formation in vitro and in vivo.
We assessed the ability of continuously NO-releasing np to inhibit MRSA 6498 bioﬁlm
formation on catheters in vitro and in vivo (Fig. 5). First, and as a proof of principle, we
added 5-mm catheters to MRSA 6498 cultures and incubated them for 24 h at 37°C
under shaking conditions. We used CFU counts to examine bioﬁlm formation on the
catheters in the absence and presence of NO (Fig. 5A). Catheters colonized with
bacteria and incubated with NO-np evinced signiﬁcantly lower cell mass than did
January 2017 Volume 61 Issue 1 e02020-16
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FIG 4 MRSA 6498 cells within mature bioﬁlms are effectively killed by NO-np. Microbial bioﬁlms were grown on polystyrene
microtiter or glass-bottom plates for 24 h at 37°C and incubated in the absence and presence of np or NO-np. For bioﬁlm
formation, the initial inoculum was 106 MRSA cells per plate. (A) The viability (percentage of control) of bioﬁlm-associated cells
was evaluated using the FDA assay. (B) The differences in bioﬁlm thicknesses were examined after exposure to np or NO-np
and compared with the bioﬁlm thickness of the untreated control. (A and B) Bars represent the average results from three
wells, and error bars denote SDs. Statistical signiﬁcance (*, P ⬍ 0.05; **, P ⬍ 0.01) was calculated by ANOVA. (C) Confocal
microscopy of MRSA 6498 strain bioﬁlms after treatment with NO-np. Images of mature bacterial bioﬁlms showed exopolymeric matrix (red; stained with concanavalin A-Texas Red conjugate) and bacterial cells (green; stained with SYTO9). Images
were obtained after 24-h coincubation of the bacterial cells in the absence and presence of np or NO-np. (D) The thickness
and morphology of each bioﬁlm can be observed in the Z-stack reconstruction. The pictures were taken at a magniﬁcation of
⫻100. (C and D) Scale bar represents 20 m for all images. (A to D) These experiments were performed twice, with similar
results obtained each time.

control catheters (P ⬍ 0.05). To conﬁrm the results obtained by CFU counts, we utilized
the FDA assay and observed that NO-np treatment signiﬁcantly reduced bioﬁlmassociated cell viability relative to that of untreated (P ⬍ 0.001) and np-treated (P ⬍
0.05) bacteria (Fig. 5B). The slight reduction observed in the viability of bacteria grown

FIG 5 NO-np prevent MRSA strain 6498 bioﬁlm formation in central venous catheters (CVCs) implanted
in rats. MRSA bioﬁlms were grown in vitro using catheter material as a substrate for 24 h at 37°C and then
treated with 5 mg/ml of np or NO-np and compared to untreated controls. For bioﬁlm formation, the
initial inoculum was 106 MRSA cells per plate. The microbial mass and viability of bioﬁlm-associated cells
were evaluated using the CFU (A) and FDA (B) assays. (A and B) Bars represent the average results from
three catheters, and error bars denote SDs. Statistical signiﬁcance (*, P ⬍ 0.05; ***, P ⬍ 0.001) was
calculated by ANOVA. These experiments were performed twice, with similar results obtained each time.
(C) Mean bacterial burdens in in vivo catheters incubated with 106 MRSA cells/ml for 48 h are shown.
CVCs implanted in the animals were treated with 5 mg/ml of np or NO-np at 24 h postinfection. This
experiment was performed once using three animals (average results from three 5-mm pieces of each
catheter per rat) per group. In addition, statistical signiﬁcance (*, P ⬍ 0.05) was calculated using ANOVA.
Bars represent the average results from three catheters, and error bars denote SDs. (D) Scanning electron
microscopy (SEM) examination of MRSA strain bioﬁlm formation on catheters placed in the jugular vein
of a Sprague-Dawley rat and treated with PBS or 5 mg/ml of np or NO-np. Scale bar represents 1 m for
all images.
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with np is most likely due to the effect of the np on the metabolic activity of the
microbial cells. Furthermore, we used a validated rodent CVC model to simulate
device-associated infection to deﬁne whether NO-np would interfere with MRSA 6498
bioﬁlm formation in vivo (Fig. 5C and D) (28, 31, 35, 36). We found signiﬁcant variations
in bacterial burden between catheters treated with NO-np and untreated (P ⬍ 0.01) or
np-treated (P ⬍ 0.05) catheters (Fig. 5C). Scanning electron microscopy (SEM) images of
the luminal surface of untreated control, np-treated, and NO-np-treated catheters were
taken 48 h after inoculation with MRSA (Fig. 5D). Untreated catheters demonstrated
abundant staphylococcal bioﬁlms that consisted of bacteria embedded in vast amounts
of EPM, whereas bioﬁlms formed on np-treated catheters were comprised of clusters of
microbial cells interconnected by polysaccharide and surrounded by dispersed EPM. In
contrast, catheters treated with NO-np displayed low numbers of bacterial cells and an
absence of EPM.
DISCUSSION
S. aureus is the most frequent bacterial pathogen in both hospital- and communityacquired infections (23.6% and 23.7%, respectively) (37). Catheter-associated S. aureus
infection is a severe health care-acquired disease that may result in septic thrombosis,
peripheral abscesses, endocarditis, and death (38). Independent risk factors associated
with catheter-related infections include prolonged hospitalization before catheterization, length of catheterization, high bacterial load at the insertion site or on the catheter
hub, internal jugular catheterization, and substandard care of the catheter by the health
care personnel (39). CVCs are an important source of the sepsis that often affects
patients in intensive care units, resulting in prolonged hospitalizations and, possibly,
death (40). In this report, we examined the efﬁcacy of NO-np in an MRSA infection
model using CVCs inserted into rats. Our ﬁndings show that NO-np may reduce CVC
microbial colonization by inhibiting bacterial adhesion to the catheter surface. Similarly,
we used in vitro experiments to demonstrate that this platform is efﬁcacious against
mature MRSA bioﬁlms.
Both planktonic and bioﬁlm-associated bacteria were susceptible to NO-np. MRSA
cells within bioﬁlms were less susceptible to NO than their planktonic counterparts. It
is possible that the absence of EPM in planktonic cells make them more vulnerable and
accessible to the antimicrobial effects of NO-np. These results correlate with those
presented in other reports that have suggested that the bioﬁlm phenotype shields
bacteria within its architecture, conferring resistance to antimicrobial therapy (41, 42).
In this regard, pathogenic bacteria are capable of persisting in a bioﬁlm in the presence
of antibiotics at levels that are 1,000-fold higher than those necessary to eradicate a
planktonic population (43). Although we have previously demonstrated that NO-np is
more effective against multiple clinical strains of MSSA and MRSA than commonly used
antibiotics (16), this level of efﬁcacy has yet to be compared and validated against
bacterial bioﬁlms. However, this was outside the scope of the present study. Remarkably, NO-np reduced the viability of bioﬁlm-related bacteria formed by multiple S.
aureus clinical isolates, suggesting that this gas can penetrate the EPM to deliver its
bactericidal properties. Similar levels of NO efﬁcacy against multidrug-resistant bacteria
within bioﬁlms using different synthetic compounds (e.g., N-diazeniumdiolates [21, 25],
nitrosothiols [24], and nitrosyl metal complexes [22]) have been described. However,
these studies showed certain limitations, such as the inability to chemically stabilize
and release NO in a controlled manner, safety issues, and perhaps most important, not
using multiple strains of a speciﬁc bacterial genus to address the variability observed
from strain to strain in these types of experiments, hindering the possibility that the
methods can be exploited in biomedical applications.
NO kills bacteria by several mechanisms (44). It may bind to iron or thiol groups on
the proteins and inactivate enzymes responsible for replication. NO also binds with the
superoxide radical O2⫺ to form peroxynitrite (OONO⫺). This species is a strong oxidant
and catalyzes membrane lipid peroxidation and the formation of nitrotyrosine residues
in proteins. NO will also react with oxygen to form toxic species, such as NO2 and N2O3.
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In this regard, transmission electron microscopy, performed in our laboratory, of MRSA
exposed to NO-np revealed cell wall damage and lysis (16). Likewise, chitosan, a
polymer naturally found in the exoskeleton of crustaceans and integrated into the
nanoparticles, has the advantage of adding signiﬁcant antimicrobial activity to the
technology and is adaptable enough to be combined with other treatments (36,
45–47). For example, chitosan reduced the infection rate of experimentally induced S.
aureus osteomyelitis in rabbits, thus providing a ﬂexible, biocompatible platform for the
design of coatings to protect surfaces from infection (48). Furthermore, this biopolymer
enhances the efﬁcacy of antibiotics against Gram-positive and Gram-negative bacteria
(49, 50).
S. aureus bioﬁlm formation is a multifactorial process that progresses through
coordinated phases. Particularly important is the early growth phase, when the bacterium strongly attaches to a substrate, which is mediated by cell surface factors that may
include autolysin (51), teichoic acids (52), or polysaccharide intercellular adhesin (PIA),
the product of the ica gene (53), whose expression promotes colonization and bioﬁlm
formation, especially during environmental stress (54, 55) and in the course of a
device-related infection (56). We found that np and NO-np signiﬁcantly inhibited
bacterial adhesion to plastic and glass surfaces. Exposure to nitrosative stress has
previously been shown to inhibit S. aureus bioﬁlm formation by downregulating the
production of PIA (57). Given that np also affect bacterial adhesion, it is possible that
chitosan, a cationic biopolymer, alters cell-cell or cell-substrate interactions to prevent
bioﬁlm formation (46). Microarray analysis after incubation of S. aureus with the
acidiﬁed-nitrite derivative NO revealed that genes involved in DNA repair, detoxiﬁcation of reactive oxygen and nitrogen species, and iron regulation are globally induced,
providing a plausible explanation for the efﬁcacy of NO-np against preformed bioﬁlms
(57).
In summary, we demonstrated that NO-np have antimicrobial activity against S.
aureus bioﬁlm-related cells. In addition, preformed staphylococcal bioﬁlms were susceptible to NO. MRSA catheter-associated infections are problematic and require
periodic removal of infected devices, particularly if severe sepsis, suppurative thrombophlebitis, endocarditis, and bloodstream infection continue. It is possible to treat
MRSA bioﬁlm-infected catheters in situ by local administration of NO-np alone or in
combination with antibiotics (58); alternatively, as NO-np alone or in combination with
antibiotics may have a role in preventing bioﬁlm formation, a prophylactic dose may be
administered immediately after insertion of the device or incorporated into the catheter material (59). NO-np has shown synergistic efﬁcacy against Candida albicans
bioﬁlms when used in combination with established antifungal drug therapies in vitro
(28). One can anticipate that NO, a gas to which microbes develop minimal resistance
even following repeated exposures (60), may contribute to the efﬁcacy of drugs to
which microorganisms within bioﬁlms have resistance. Additionally, this nanotechnology is a ﬂexible platform to encapsulate antimicrobial drugs for local delivery into
infected catheters in order to prevent bioﬁlm formation or eradicate mature bioﬁlms
(61). Together, these ﬁndings underscore the clear translational potential for the
utilization of NO-np in the prevention and treatment of bioﬁlms infecting medical
prosthetic devices.
MATERIALS AND METHODS
S. aureus. S. aureus isolates were collected, typed, and stored according to an approved protocol at
the Albert Einstein College of Medicine (Einstein) and Monteﬁore Medical Center. A total of six S. aureus
clinical isolates (strains 38, 67, 85, 112, 132, and 6498) were used in this study. The characteristics of each
strain have been described previously (62). The MRSA 6498 isolate used in the majority of the experiments in this report is a USA300 strain collected from a patient’s wound and has been utilized extensively
in prior work (16, 17). The strains were stored at ⫺80°C in brain heart infusion (BHI) broth with 40%
glycerol until use. Test organisms were grown in tryptic soy broth (TSB; MP Biomedicals, LLC) overnight
at 37°C on a rotary shaker (Thermo Fisher Scientiﬁc) set at 150 rpm. Growth was monitored by measuring
the optical density at 600 nm and by using a microtiter plate reader (Bio-Tek).
Synthesis of NO-np and NO release. A hydrogel-glass composite was synthesized using a mixture
of tetramethylorthosilicate, polyethelene glycol, chitosan, glucose, and sodium nitrite in a 0.5 mM
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sodium phosphate buffer (pH 7) as described previously (26). The nitrite was reduced to NO within the
matrix because the glass properties of the composite effected redox reactions initiated with thermally
generated electrons from glucose. After the redox reaction, the ingredients were combined and dried
using a lyophilizer, resulting in a ﬁne powder comprising nanoparticles containing NO. Once exposed to
an aqueous environment, the hydrogel properties of the composite allow for the opening of the water
channels inside the particles, facilitating the release of the trapped NO over extended time periods. NO
released from the nanoparticles was determined by amperometric detection using the Apollo 4000 nitric
oxide detector (World Precision Instruments Ltd.) as previously described (16). The observed trace has
been described previously and indicates a relatively stable rate of NO release, with only a slight initial
peak (5.64 ⫻ 10⫺6 g/ml or 18.75 nM) at 70 min (16, 28). A steady-state level (3.76 ⫻ 10⫺6 g/ml or 12.5
nM) is achieved after 6 h, with continuous release occurring over ⬃24 h. Nanoparticles lacking NO were
also produced to serve as controls.
Bioﬁlm formation and NO-np treatment. For each strain, 100 l of a suspension with 106 bacterial
cells in BHI medium supplemented with 1% glucose was added into individual wells of polystyrene
96-well plates or poly-D-lysine 35-mm glass-bottom plates (MatTek), and the plates were incubated at
37°C without shaking. The bioﬁlms were allowed to form for 24 h. Bioﬁlms were rinsed 3 times with
phosphate-buffered saline (PBS) to remove nonadherent bacteria, and 100 l of fresh medium without
(control) or with 5 mg/ml of NO-np or np alone was added.
Comparison of levels of bioﬁlm and planktonic staphylococcal cell susceptibility to NO-np. S.
aureus bioﬁlms were incubated with 200 l of BHI (1% glucose) containing 1.25, 2.5, or 5 mg/ml of np
or NO-np. Untreated bioﬁlms were used as a control. S. aureus planktonic cells were suspended at a
density of 5 ⫻ 106 cells per ml in medium alone or in the presence of either np or NO-np. Either S. aureus
bioﬁlms or planktonic cells were mixed with np or NO-np for 1 min, using a microtiter plate reader mixer
to ensure a uniform distribution of the nanoparticles, and were incubated at 37°C for 24 h. CFU counts
in killing assays were used to determine the microbial mass.
Killing assay. The toxicity of NO-np for S. aureus planktonic cells or within bioﬁlms was evaluated by
the CFU count in a killing assay. After incubation with NO-np, bioﬁlms were scraped from the bottom of
the wells with a sterile 200-l micropipette tip and sonicated for 1 min to separate individual staphylococci. Amounts of 100 l of suspensions containing dissociated cells were aspirated from the wells,
transferred to a microcentrifuge tube with 900 l of PBS, and sonicated again for 1 min. A series of
dilutions were then performed, and 100 l of diluted suspension was plated on BHI (1% glucose) agar
plates.
Adherence assay. S. aureus cells were incubated on 35-mm glass-bottom dishes with 2 ml of BHI (1%
glucose) for 90 min in the absence and presence of 5 mg/ml of np or NO-np. After treatment, the
medium was removed, the plates were rinsed once with Hanks’ balanced salt solution (HBSS; Sigma), and
200 l containing 6.6 M SYTO9 in distilled water (500-nm excitation wavelength and 535-nm emission
wavelength; Thermo Fisher Scientiﬁc) was added. After 30 min of incubation, the plates containing
adhered cells were rinsed once to remove the staining solution, 2 ml of HBSS was added, and confocal
images were taken using a Leica TCS SP5 microscope (Wetzlar, Germany) and analyzed using Volocity 3D
Image Analysis software (PerkinElmer). As negative controls, plates were incubated with np or NO-np
alone. Two independent experiments were performed using multiple replicates.
In vitro catheter bioﬁlm formation assay. Five-millimeter-long catheters were inoculated with S.
aureus using a 23-gauge needle and incubated in 6-well plates with 1 ml of BHI with 1% glucose at 37°C
for 24 h in a rotary shaker. Bioﬁlms were rinsed 3 times with PBS to remove nonbioﬁlm bacteria, and 100
l of fresh medium without (control) or with 5 mg/ml of np or NO-np was added and similarly incubated
for 24 h. Then, catheters containing bioﬁlms were rinsed once with PBS and the toxicity of NO-np was
evaluated using CFU and ﬂuorescein diacetate (FDA; Sigma) assays.
FDA assay. FDA was dissolved in acetone (Sigma) to a concentration of 2 mg/ml, and the solution
was stored at ⫺20°C as described previously (63). Subsequently, 100 l of the solution, prepared by
diluting the stock solution 1:50 in PBS, was added to each well. The plates were incubated at 37°C for
1 h on a shaker in the dark. The ﬂuorescence in the wells was measured using a microtiter plate reader
equipped with excitation and emission ﬁlters of 485 and 535 nm, respectively.
Bioﬁlm architecture. The thicknesses and structural integrity of untreated bioﬁlms and np- or
NO-np-treated bioﬁlms were examined using confocal microscopy. Brieﬂy, MRSA bioﬁlms were grown for
24 h in 35-mm glass-bottom culture dishes in the absence or presence of np alone or NO-np, rinsed three
times with HBSS, and incubated for 30 min at room temperature in 2 ml of HBSS containing the
ﬂuorescent stains SYTO9 (6.6 M) and concanavalin A-Texas Red conjugate (6.6 M) with protection from
light. The dishes were then rinsed three times with HBSS to remove excess stain. SYTO9 labels bacteria,
while concanavalin A-Texas Red conjugate (596-nm excitation wavelength and 615-nm emission wavelength) stains the EPM. Microscopic examinations of bioﬁlms formed in culture plates were performed
with confocal microscopy. Two independent experiments were performed using multiple replicates.
In vivo CVC rat model for bioﬁlm formation. A CVC bioﬁlm model was used for in vivo experiments,
as described elsewhere (31, 35, 36). All animal studies were conducted according to the experimental
practices and standards approved by the Institutional Animal Care and Use Committee at Einstein. Brieﬂy,
female Sprague-Dawley rats weighing 400 g (Charles Rivers) were anesthetized (3 to 4% isoﬂurane for
induction and 2.0% for maintenance during surgery), and the right external jugular was exposed. A
longitudinal incision was made in the vein wall, and a sterile, heparinized (100 U/ml) polyethylene
catheter (PE 100 [inner diameter, 0.76 mm; outer diameter, 1.52 mm]; BD) was inserted at a site above
the right atrium (⬃2 cm) and secured with 3-0 silk ties. The proximal end of the catheter was tunneled
subcutaneously and secured on the subscapular skin by means of a button secured with a 2-0 Ti-Cron
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